Research programme: CAR-T cell therapeutics - AZTherapies
Alternative Names: CAR-Treg programme - AZTherapies; CAR-TregsLatest Information Update: 22 Apr 2026
At a glance
- Originator Smith Therapeutics
- Developer AZTherapies
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 22 Apr 2026 Chemical structure information (structure, chemical name, Molecular formula) added.
- 28 Nov 2023 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Parenteral)
- 24 Oct 2019 Smith Therapeutics has been acquired and merged into AZTherapies